Cantor Fitzgerald keeps an Overweight rating on Vera Therapeutics (VERA) with a $100 price target after non-profit Kidney Disease: Improving Global Outcomes released updated guidelines for immunoglobulin A nephropathy. The firm sees “direct positive implications” for Vera’s atacicept, saying the drug has shown the ability to reduce pathogenic IgA and glomerular injury. Cantor continues to believe the size of the IgA market remains underestimated. Vera in afternoon trading is up 7% to $26.15.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics Reports Progress in Clinical Trials
- Vera Therapeutics Signs New Sales Agreement with TD Securities
- Vera Therapeutics reports Q2 EPS ($1.20), consensus (62c)
- Vera Therapeutics announces anticipated upcoming milestones
- Vera Therapeutics sees cash funding operations through launch of atacicept